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ABSTRACT
Objective  A recent meta-analysis of published genome-
wide association studies (GWAS) in populations of 
European descent reported novel associations of markers 
mapping to the CD40, CCL21 and CDK6 genes with 
rheumatoid arthritis (RA) susceptibility while a large-
scale, case-control association study in a Japanese 
population identiﬁ  ed association with multiple single 
nucleotide polymorphisms (SNPs) in the CD244 gene. The 
aim of the current study was to validate these potential 
RA susceptibility markers in a UK population.
Methods  A total of 4 SNPs (rs4810485 in CD40, 
rs2812378 in CCL21, rs42041 in CDK6 and rs6682654 in 
CD244) were genotyped in a UK cohort comprising 3962 
UK patients with RA and 3531 healthy controls using the 
Sequenom iPlex platform. Genotype counts in patients 
and controls were analysed with the χ2 test using Stata.
Results  Association to the CD40 gene was robustly 
replicated (p=2×10−4, OR 0.86, 95% CI 0.79 to 0.93) 
and modest evidence was found for association with 
the CCL21 locus (p=0.04, OR 1.08, 95% CI 1.01 to 
1.16). However, there was no evidence for association 
of rs42041 (CDK6) and rs6682654 (CD244) with RA 
susceptibility in this UK population. Following a meta-
analysis including the original data, association to CD40 
was conﬁ  rmed (p=7.8×10−8, OR 0.87 (95% CI 0.83 to 
0.92).
Conclusion  In this large UK cohort, strong association of 
the CD40 gene with susceptibility to RA was found, and 
weaker evidence for association with RA in the CCL21 
locus.
INTRODUCTION
Genome-wide association studies (GWAS) have led 
to a breakthrough in the search for complex dis-
ease susceptibility markers.1 Speciﬁ  cally for rheu-
matoid arthritis (RA), these studies have detected 
a number of new susceptibility loci, including 
the 6q23,2–4  TRAF1/C5,5–9  PRKCQ,  KIF5A  and 
IL2RB genetic regions.10 Recently, a meta-analysis 
of the Wellcome Trust Case Control Consortium 
(WTCCC) GWAS and a US GWAS4 5 conﬁ  rmed 
association to PRKCQ, KIF5A and MMEL and iden-
tiﬁ  ed additional RA-associated markers mapping to 
the CD40, CCL21 and CDK6 loci,11 that have yet to 
be conﬁ  rmed in an independent UK population. In 
addition, a recent case-control association study in a 
Japanese population identiﬁ  ed two functional vari-
ants mapping to the CD244 gene, rs3766379 and 
rs6682654, that were associated with RA, again yet 
to be tested for association in a UK population.12
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These studies therefore add to the recent explo-
sion in the number of loci reported to be associated 
with RA susceptibility. In order for these loci to be 
conﬁ  rmed as risk factors for RA, well powered val-
idation studies are required to support these initial 
ﬁ  ndings.
The aims of this study were, therefore, ﬁ  rst to 
validate the additional RA markers derived from 
the recent meta-analysis (CD40, CCL21 and CDK6) 
in an independent UK population and, second, to 
investigate a functional CD244 variant reported to 
be associated with RA in the Japanese study.11 12
METHODS
Patients with RA (n=3962) were recruited from six 
centres (Manchester, Shefﬁ   eld, Leeds, Aberdeen, 
Oxford and London) across the UK. All patients 
were Caucasian of North European ancestry 
and all fulﬁ   lled the 1987 American College of 
Rheumatology classiﬁ   cation criteria modiﬁ  ed  for 
genetic   studies.13 14 Clinical and demographic 
characteristics of the cohort are detailed in supple-
mentary table 1. Brieﬂ  y, 71.8% participants were 
women, 72.1% were rheumatoid factor positive 
and 67.9% carried anti-citrullinated protein anti-
bodies (ACPA) as recognised by the anti-cyclic cit-
rullinated protein (CCP) antibody test. This cohort 
is therefore representative of a hospital-based series 
of patients with RA. Autoantibody status data was 
available for 3723 and 2281 patients for rheumatoid 
factor (RF) and anti-CCP, respectively. Healthy con-
trols (n=3531) were recruited from ﬁ  ve of the six 
centres (patients only recruited from London). All 
participants were recruited after providing informed 
consent and the study was approved by the North 
West Research Ethics Committee (MREC 99/8/84).
Genotyping was performed using the Sequenom 
iPlex platform (http://www.sequenom.com) accord-
ing to the manufacturer’s instructions. All genotyp-
ing was performed at the arc Epidemiology Unit, 
Manchester. Only samples and single nucleotide 
polymorphisms (SNPs) exceeding a 90% success 
rate were used in the analysis.
Genotype counts in patients and controls were 
analysed using Stata software (Stata, College 
Station, Texas, USA) with the χ2 test. For the 
meta-analysis, the Breslow–Day test for homoge-
neity and the Cochran Mantel–Haenszel test were 
performed using Stata. For all the tests performed, 
p values <0.0125 were considered statistically sig-
niﬁ   cant, after applying Bonferroni correction for 
four comparisons.
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Genotype frequency, no (%)
p For 
allele








11 12 22 11 12 22
CD40 rs4810485 T/G 0.23 0.25 165 (4.5) 1334 (36.2) 2184 (59.3) 173 (5.7) 1189 (39.1) 1681 (55.2) 2×10−4 0.86 (0.79 to 0.93) 0.001 0.02
CCL21 rs2812378 G/A 0.37 0.35 478 (12.9) 1752 (47.2) 1478 (39.9) 377 (12.5) 1339 (44.5) 1294 (43) 0.04 1.08 (1.01 to 1.16) 0.03 0.65
CDK6 rs42041 G/C 0.25 0.25 228 (6.1) 1402 (37.8) 2079 (56.1) 182 (6.1) 1125 (38) 1655 (55.9) 0.91 0.99 (0.92 to 1.08) 0.99 0.99
CD244 rs6682654 G/A 0.43 0.44 638 (18.1) 1756 (49.8) 1132 (32.1) 571 (19.9) 1394 (48.5) 909 (31.6) 0.20 0.96 (0.89 to 1.02) 0.19 0.07
MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Power calculations were performed using the Quanto V.0.5 
software (Department of Preventive Medicine University of 
Southern California, California, USA), considering minor 
allele frequencies and ORs similar to those found in previous 
studies 4 5 11 12 at the 5% signiﬁ  cance level.
RESULTS
We selected four polymorphisms previously reported as RA sus-
ceptibility markers for testing in the current study:
(1)   rs4810485, located in the second intron of the CD40 gene;
(2)   rs2812378, mapping to the 5’ untranslated region of 
CCL21;
(3)   rs42041, positioned in a CDK6 intron11;
(4)   rs6682654, located in CD244, which is an almost perfect 
proxy of the functional RA marker for the Japanese popu-
lation within this gene, rs3766379 (D′=1, r2=0.97).12
Genotype frequencies conformed to Hardy–Weinberg expec-
tations in patients and controls for all the polymorphisms 
under study. The estimated power of the study was 86% for 
rs481048, 77% for rs2812378, 60% for rs42041 and 99% for 
rs6682654.
Table 1 shows the results of this validation study. Allele fre-
quencies were similar to those previously described in a US pop-
ulation for the CD40, CCL21 and CDK6 markers.11 We found 
that the minor T allele of CD40 rs4810485 was signiﬁ  cantly 
increased in healthy controls compared to patients with RA 
(p=2×10−4, OR 0.86, 95% CI 0.79 to 0.93). This is in accordance 
with the previous study by Raychaudhuri et al.
When we analysed CCL21 rs2812378, we observed a higher 
frequency of the minor C allele in patients with RA as previ-
ously described,11 although this skewing seemed to have a more 
modest effect in our population (p=0.04, OR 1.08, 95% CI 1.01 
to 1.16). With regard to CDK6 rs42041, no evidence of associa-
tion with RA was found in our UK population (table 1).
Additionally, we examined the functional CD244 vari-
ant rs6682654, which was previously shown to be associated 
with RA in a Japanese population.12 Linkage disequilibrium 
(LD) between this SNP and the other marker within CD244, 
rs3766379, also reported to be associated with RA in the 
Japanese study, is higher in the Caucasian population (r2=0.97, 
D′=1) than in the Japanese population (r2=0.87, D′=1).15 When 
we compared the distribution of allele and genotype frequen-
cies of rs6682654 between patients and controls, we did not ﬁ  nd 
statistically signiﬁ  cant differences (table 1). Allele frequencies of 
the reference G allele were lower in the UK population than in 
the previously described Japanese population (0.43 and 0.44 in 
patients and controls, respectively, for the UK population vs 0.66 
and 0.59 in patients and controls, respectively, for the Japanese 
population), which is in accordance with the data deposited in 
HapMap (http://www.hapmap.org).
Stratiﬁ  cation analysis of the four polymorphisms under study 
showed that the rs4810485 CD40 SNP was strongly associated 
with the presence of RF and anti-CCP antibodies (p=8.10×10−6, 
OR 0.82, 95% CI 0.75 to 0.89 and p=9.52×10−5, OR 0.81, 95% 
CI 0.73 to 0.90, respectively). CCL21 rs2812378 also showed 
this trend, but p values for the association with seropositive dis-
ease were modest (p=0.02, OR 1.10, 95% CI 1.01 to 1.18 and 
p=0.03, OR 1.10, 95% CI 1.01 to 1.21, for RF and anti-CCP RA, 
respectively) (supplementary table 2).
Meta-analysis of these markers was undertaken, pooling data 
from the previously published RA GWASs,4 5 11 together with 
data from a validation cohort from the US11 and our validation 
study in a UK cohort. p Values for the Breslow–Day test were 
0.31 for rs4810485, 0.81 for rs2812378 and 0.02 for rs42041 
(table 2). The meta-analysis revealed strong evidence of associa-
tion with the CD40 variant and a more modest, but suggestive 
association with the CCL21 variant. The evidence for associa-
tion with CDK6 was relatively weak.
The rs6682654 SNP mapping to CD244 and showing evi-
dence for association with RA in a Japanese population12 was 
not tested in the meta-analysis by Raychaudhri et al.11 In order 
to investigate whether a weak effect on susceptibility could be 
detected in a UK population, we performed a meta-analysis of 
the variant, combining imputed data from the WTCCC dataset 
with that derived from direct genotyping in the current valida-
tion study. Pooled analysis revealed no association with RA in 
the UK population (p=0.87, OR 1.004, 95% CI 0.95 to 1.06). 
Joint analysis of the Japanese and UK cohorts was not feasible, 
due to the high degree of genetic heterogeneity between the 
populations (pBreslow–Day=1.8×10−6).
DISCUSSION
In this large UK cohort, we have found strong association of the 
rs4810485 CD40 variant with susceptibility to RA, and weaker 
evidence for association with RA in the CCL21 locus. We found 
no evidence for association with either the CDK6 locus or the 
Table 2  Meta-analysis of newly identiﬁ  ed rheumatoid arthritis (RA) markers in populations of European ancestry
Locus SNP
GWAS meta-analysis11 US validation11 UK validation Meta-analysis
p Value OR p Value OR p Value OR (95% CI) p Value OR (95% CI)
Breslow–Day 
p value
CD40 rs4810485 2.4×10−7 0.83 0.003 0.91 2×10−4 0.86 (0.79 to 0.93) 7.8×10−8 0.87 (0.83 to 0.92) 0.31
CCL21 rs2812378 6.9×10−5 1.13 9.7×10−4 1.10 0.04 1.08 (1.01 to 1.16) 1.2×10−4 1.09 (1.04 to 1.14) 0.81
CDK6 rs42041 5.5×10−5 1.15 0.01 1.08 0.91 0.99 (0.92 to 1.08) 0.002 1.08 (1.03 to 1.14) 0.02
GWAS, genome-wide association studies; SNP, single nucleotide polymorphism.
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presented here yielded a statistically signiﬁ   cant, yet modest, 
association (p=0.002, OR 1.08, 95% CI 1.03 to 1.14) of the 
CDK6 rs42041 marker with RA susceptibility. It should be noted 
that we detected some heterogeneity in the effect sizes between 
studies (pBreslow–Day=0.02), so the pooled OR should be consid-
ered with caution and further validation in independent cohorts 
will be required in order to clarify the role of this variant in RA 
susceptibility. For the CD244 marker, by contrast, no evidence 
for association was detected even after pooled analysis of the 
UK WTCCC and validation datasets, which included approxi-
mately 5400 patients with RA and approximately 5800 healthy 
controls. In this case, genetic heterogeneity would appear 
to explain the lack of replication as allele frequencies for the 
rs6682654 SNP are signiﬁ  cantly different between the Japanese 
and UK populations.
In the past year, the ﬁ  rst wave of GWAS has improved our 
understanding of the genetic basis of common, complex dis-
eases, including RA. These studies have made possible the iden-
tiﬁ  cation of new RA susceptibility loci, such as those mapping 
to the 6q23, TRAF1/C5, PRKCQ, KIF5A, STAT4 and now CD40. 
However, these initial GWAS have shown that the effect sizes 
resulting from associations with common SNPs are modest and, 
therefore, the remaining RA susceptibility genes may have even 
smaller effect sizes. Validation studies using large sample sizes 
and ethnically different populations as well as meta-analysis will 
be essential to robustly deﬁ  ne new potential susceptibility loci. 
Only then will the investment in ﬁ  ne mapping and functional 
studies be justiﬁ  ed to identify the aetiological variants within 
the validated loci. In conclusion, we have validated association 
of CD40 rs4810485 and detected weak evidence for association 
of CCL21 rs2812378 with RA in a UK population, laying the 
foundations for further studies of the functional and genetic 
effects of these variants in conferring risk of disease.
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CD244 variant, previously reported to be associated with RA in 
Caucasian and Japanese populations, respectively.
The CD40 and CCL21 genes both encode proteins that are 
involved in immune regulation. CD40 is expressed in a wide 
variety of immune cells, including B cells, monocytes and den-
dritic cells, while its ligand, CD154, is expressed by activated 
CD4 T cells. Binding of CD154 to CD40 provides a critical 
stimulus for B cell proliferation, immunoglobulin production, 
isotype switching and upregulation of other costimulatory mol-
ecules including B7-related molecules.16 CD40–CD154 inter-
action appears to have an important role in RA, as expression 
of CD154 on CD4 T cells in RA promotes increased activation 
of CD4 T lymphocytes and is associated with active disease. 
Indeed, blockade of this pathway has been suggested as a poten-
tially useful therapeutic approach in RA and in autoimmune 
disease in general.16 17 It is interesting to note that the CD40 
marker was strongly associated with anti-CCP and RF-positive 
RA, which suggest that this polymorphism, or other/s in LD 
with it, could play a role in the regulation of B cell response and 
the production of autoantibodies. The CCL21 gene encodes a 
protein that is a homeostatic lymphoid chemokine instrumental 
in the recruitment and organisation of T cells and dendritic cells 
into secondary lymphoid organs, which participate in lymphoid 
tissue microanatomical organisation in RA.18 Both genes, there-
fore, are plausible candidates in conferring risk of RA. Although 
we found statistically signiﬁ  cant evidence for association with 
the CCL21 locus, this would not have remained signiﬁ  cant if a 
correction for multiple testing had been applied and, therefore, 
conﬁ  rmation of this locus as an RA susceptibility region will 
require further investigation in other large data series.
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erogeneity of genetic susceptibility factors in RA, meaning that 
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the most robustly validated RA marker in European populations 
after human leukocyte antigen (HLA), is not polymorphic in 
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associated with RA in a Korean population.25 However, it is pos-
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come by meta-analysis where published data is available and 
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06_annrheumdis109579.indd   815 06_annrheumdis109579.indd   815 7/28/2010   3:26:00 PM 7/28/2010   3:26:00 PMExtended report
Ann Rheum Dis 2010;69:813–816. doi:10.1136/ard.2009.109579 816
 8.  Kurreeman FA, Rocha D, Houwing-Duistermaat J, et al. Replication of the tumor 
necrosis factor receptor-associated factor 1/complement component 5 region as a 
susceptibility locus for rheumatoid arthritis in a European family-based study. Arthritis 
Rheum 2008;58:2670–4.
 9.  Barton A, Thomson W, Ke X, et al. Re-evaluation of putative rheumatoid arthritis 
susceptibility genes in the post-genome wide association study era and hypothesis of 
a key pathway underlying susceptibility. Hum Mol Genet 2008;17:2274–9.
10.  Barton A, Thomson W, Ke X, et al. Rheumatoid arthritis susceptibility loci at 
chromosomes 10p15, 12q13 and 22q13. Nat Genet 2008;40:1156–9.
11.  Raychaudhuri S, Remmers EF, Lee AT, et al. Common variants at CD40 and other loci 
confer risk of rheumatoid arthritis. Nat Genet 2008;40:1216–23.
12.  Suzuki A, Yamada R, Kochi Y, et al. Functional SNPs in CD244 increase the risk of 
rheumatoid arthritis in a Japanese population. Nat Genet 2008;40:1224–9.
13.  Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 
1987 revised criteria for the classiﬁ  cation of rheumatoid arthritis. Arthritis Rheum 
1988;31:315–24.
14.  MacGregor AJ, Bamber S, Silman AJ. A comparison of the performance of different 
methods of disease classiﬁ  cation for rheumatoid arthritis. Results of an analysis from 
a nationwide twin study. J Rheumatol 1994;21:1420–6.
15.  Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of 
over 3.1 million SNPs. Nature 2007;449:851–61.
16.  Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the 
beneﬁ  t of disrupting this pathway. Autoimmunity 2004;37:457–64.
17.  Liu MF, Chao SC, Wang CR, et al. Expression of CD40 and CD40 ligand among cell 
populations within rheumatoid synovial compartment. Autoimmunity 2001;34:107–13.
18.  Manzo A, Paoletti S, Carulli M, et al. Systematic microanatomical analysis of CXCL13 
and CCL21 in situ production and progressive lymphoid organization in rheumatoid 
synovitis. Eur J Immunol 2005;35:1347–59.
19.  Yamada R, Yamamoto K. Mechanisms of disease: genetics of rheumatoid 
arthritis--ethnic differences in disease-associated genes. Nat Clin Pract Rheumatol 
2007;3:644–50.
20.  Barton A, Bowes J, Eyre S, et al. Investigation of polymorphisms in the PADI4 
gene in determining severity of inﬂ  ammatory polyarthritis. Ann Rheum Dis 
2005;64:1311–15.
21.  Iwamoto T, Ikari K, Nakamura T, et al. Association between PADI4 and rheumatoid 
arthritis: a meta-analysis. Rheumatology (Oxford) 2006;45:804–7.
22.  Kobayashi S, Ikari K, Kaneko H, et al. Association of STAT4 with susceptibility to 
rheumatoid arthritis and systemic lupus erythematosus in the Japanese population. 
Arthritis Rheum 2008;58:1940–6.
23.  Lee HS, Remmers EF, Le JM, et al. Association of STAT4 with rheumatoid arthritis in 
the Korean population. Mol Med 2007;13:455–60.
24.  Orozco G, Alizadeh BZ, Delgado-Vega AM, et al. Association of STAT4 with 
rheumatoid arthritis: a replication study in three European populations. Arthritis Rheum 
2008;58:1974–80.
25.  Lee HS, Korman BD, Le JM, et al. Genetic risk factors for rheumatoid arthritis differ in 
Caucasian and Korean populations. Arthritis Rheum 2009;60:364–71.
06_annrheumdis109579.indd   816 06_annrheumdis109579.indd   816 7/28/2010   3:26:00 PM 7/28/2010   3:26:00 PM